deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02547870

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

A Phase 1 Open-Label, Randomized, Parallel-Group Study in Healthy Subjects to Investigate the Effect of Different Storage Conditions of a Long-Acting Nanosuspension of Rilpivirine on the Single-Dose Plasma Pharmacokinetics of Rilpivirine After Intramuscular Injection

Sponsor: Janssen Infectious Diseases BVBA

Conditions Human Immunodeficiency Virus Type 1
Interventions Aged RPV-LA Rilpivirine (RPV) Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)
Updated 7 times since 2017 Last updated: Nov 12, 2018 Started: Aug 14, 2015 Primary completion: Apr 26, 2016 Completion: Apr 26, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Human Immunodeficiency Virus Type 1 and is currently completed. Janssen Infectious Diseases BVBA leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotCompleted~Dec 2018 – ~Sep 2020 · 21 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE1

  5. Dec 2018 — Sep 2020 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Jun 2018 — Dec 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Infectious Diseases BVBA
Data source: Janssen Infectious Diseases BVBA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations